ArticleTherapeutic advances in gastroenterology2026
Jaundice marks immunoglobulin G4-related cholangitis in type 1 autoimmune pancreatitis patients.
Article in Therapeutic advances in gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The phenotype of immunoglobulin G4 (IgG4)-related cholangitis (IRC) patients among type 1 autoimmune pancreatitis (AIP-1) patients in Taiwan, where secondary biliary cholangitis is prevalent, is unknown. Objectives: To evaluate the phenotype of IRC in AIP-1 patients. Design: Retrospective cohort study. Methods: A 15-year cohort study of 237 AIP-1 patients was conducted. AIP-1 was diagnosed according to the HISORt criteria. Results: Of 237 AIP-1 patients, 90 (37.9%) had IRC (males: Conclusion: In total, 37.9% of AIP-1 patients had IRC. Higher levels of hepatocellular injury, cholestatic features, and IgG4 were noted in patients with IRC than in patients without IRC. Baseline bili-T level (cutoff > 2.2 mg/dL) is an indicator of IRC among AIP-1 patients. Biliary injury and systemic inflammation are associated with mortality in all AIP-1 and IRC-AIP-1 patients. Liver fibrosis subsequent to IRC might further increase mortality in AIP-1 patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.